CN | EN
Development Strategy
Pipeline
Robust Pipeline with global rights and lead positions
Fields Project/Modality Target Indications Pre-clinical Phase Ⅰ Phase Ⅱ Phase Ⅲ Trial Regions Rights Regions Partner
Nephropathy SC0062
SM
ETA lgA
DKD
Oncology BC3195
ADC
CDH3 Soild tumor
Oncology BC2027
ADC
GPC3 Solid tumor
Oncology SC0245
SM
ATR SCLC
Oncology SC0191
SM
WEE1 OC
Oncology BC3402
mAb
TIM-3 HCC
Oncology BsAb Undisclosed Solid tumor
SM=Small Molecule
Highly Differentiated
Science-Driven
Deeply understand the scientific mechanism, and improve the success rate of target selection
Clinically-Oriented
Strive to meet the unmet medical needs of the future and to foresee the trend the future clinical treatment scenarios
 
Long-term Commerical Value
Develop products with long-term commercial value
 
 
Focused Area
Chronic kidney disease(CKD)
Oncology
From anti-tumor to anti-tumor resistance